Candidate proteomic biomarkers in systemic sclerosis discovered using mass-spectrometry: an update of a systematic review (2014–2020)

Abstract

Background: Systemic sclerosis (Ssc) is an autoimmune disease characterized by graduate cutaneous and tissue fibrosis development and irreversible fibroproliferative vascular changes. The aim of the current systematic review was to update the list of proteomic candidate biomarkers identified from Ssc samples with mass spectrometry techniques.Methods: Medline and Scopus databases were searched on 1st September 2020. Relevant articles were searched from March 2014 until September 2020. Two independent reviewers evaluated the retrieved articles.Results: From a total of 97 articles, 9 articles were included in the final analysis summarizing 539 candidate proteomic biomarkers from various samples from Ssc patients (a larger number compared to the previous systematic review). Most biomarkers were identified from cutaneous biopsies. Only 5 articles included a validation step of the findings with only 13 biomarkers being validated.Conclusions: Although many candidate biomarkers were additionally identified, independent validation studies are needed in order to evaluate the importance of these biomarkers for Ssc patients.

Circulatory cytokeratin 17, marginal zone B1 protein and leucine-rich α2-glycoprotein-1 as biomarkers for disease severity and fibrosis in systemic sclerosis patients

“…Lower CK17 was associated with active Ssc disease and with various clinical characteristics that are associated with more severe disease (sclerodactyly, telangiectasia and PHT). Previous fundamental proteomic studies indicated CK17 as candidate biomarker in Ssc patients, but confirmation studies were needed in order to assess its diagnosis and prognosis capacity ( 5 , 14 ). Although higher CK17 concentrations were noted in Ssc patients compared to healthy controls, lower CK17 concentrations associated poorer prognosis within Ssc group.…”

“…Numerous proteomic biomarkers were evaluated for Ssc patients but the clinical utility of most of these biomarkers is still limited ( 3 ). In addition, there are numerous previous studies that focused on identification of candidate proteomic Ssc biomarkers using mass-spectrometry techniques from a wide array of biological samples ( 4 , 5 ). From all these studies a large number of candidates Ssc biomarkers emerged.…”

Enrichr in silico analysis of MS-based extracted candidate proteomic biomarkers highlights pathogenic pathways in systemic sclerosis

“…The datasets generated and/or analysed during the current study are available through Balanescu P et al 8,11 . This data can be found in Additional file 1.…”

The mosaic of autoimmunity – Finally discussing in person. The 13th international congress on autoimmunity 2022 (AUTO13) Athens

“…An increase in 8 fibrosis-associated autoantibodies in SSc patients compared to the control group was noticed. Among the autoantibodies isolated, 2 were suggested to be used as biomarkers for fibrosis in SSc patients, namely anti-phosphatidylinositol-5-phosphate 4-kinase type 2 beta (anti-PIP42K2B) and anti-AKT Serine/Threonine Kinase 3 (anti-AKT3) antibodies [ 121 ]. Intense research not only for discovering new biomarkers but also revealing the association of identified biomarkers with the pathogenesis of SSc is being conducted.…”